Skip to Main Content
Table 2.

Prevalence of prostate cancer in placebo arm and GTC arm at the 6-month biopsy checkpoint and at the end of the 1-year study (12 months biopsy checkpoint)

Study arm6-months biopsy check12-months biopsy checkTotal no. of CaPs diagnosed/total no. of recruited subjectsPrevalence of prostate cancer
Placebo 6 of 30 3 of 24* 9 of 30 30.0% 
GTCs 0 of 30 1 of 30 1 of 30 3.3% 
P value (95% confidence, placebo vs. GTC)    <0.01 
Study arm6-months biopsy check12-months biopsy checkTotal no. of CaPs diagnosed/total no. of recruited subjectsPrevalence of prostate cancer
Placebo 6 of 30 3 of 24* 9 of 30 30.0% 
GTCs 0 of 30 1 of 30 1 of 30 3.3% 
P value (95% confidence, placebo vs. GTC)    <0.01 
*

Six patients, diagnosed with prostate cancer at the 6 months biopsy check, left the study and were not subjected to the subsequent 12 months biopsy check. Statistical analysis (t test analysis) shows that the difference in prostate cancer prevalence between the two arms was highly significant (P < 0.01).

Close Modal

or Create an Account

Close Modal
Close Modal